RPAM
MRSN

Rhenman & Partners Asset Management’s Mersana Therapeutics MRSN Stock Holding History

Rhenman & Partners Asset Management’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-16,000
Closed -$508K – 92
2023
Q3 		$508K Hold
16,000
– – 0.05% 84
2023
Q2 		$1.32M Buy
16,000
+2,000
+14% +$293K 0.14% 80
2023
Q1 		$1.4M Sell
14,000
-2,000
-13% -$281K 0.15% 82
2022
Q4 		$2.34M Buy
+16,000
New +$2.7M 0.24% 80

Other funds holding MRSN

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Rhenman & Partners Asset Management's MRSN Position: Q4 2023 in Review

Rhenman & Partners Asset Management sold out of Mersana Therapeutics (MRSN) in Q4 2023, closing a stake of 16,000 shares — an estimated $508K sold.

Rhenman & Partners Asset Management first reported a position in MRSN in Q4 2022 and held it in 4 quarters. The position peaked at $2.34M in Q4 2022. 105 funds tracked by Wall St. Rank hold MRSN as of Q4 2023.

  • Rhenman & Partners Asset Management reported no remaining Mersana Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Rhenman & Partners Asset Management sold 16,000 Mersana Therapeutics shares in Q4 2023, an estimated $508K.
  • Rhenman & Partners Asset Management first reported a position in Mersana Therapeutics in Q4 2022 and held it in 4 quarters.
  • Rhenman & Partners Asset Management's Mersana Therapeutics position peaked at $2.34M in Q4 2022.
  • 105 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q4 2023.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.